We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ROPIVACAINE KABI ropivacaine hydrochloride 150 mg/20 mL solution for injection ampoule, Fresenius Kabi Australia Pty Ltd, CON-747
Product name
ROPIVACAINE KABI ropivacaine hydrochloride 150 mg/20 mL solution for injection ampoule
Sponsor name
Fresenius Kabi Australia Pty Ltd
Consent start
Consent no.
CON-747
Duration
The consent is effective for all batches of the product manufactured from 3 February 2021 until 29 March 2023.
Standard
Paragraphs 10(4)(d) and 10(4)(k) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The product(s) do not conform to the requirements of paragraphs 10(4)(d) and
10(4)(k) of Therapeutic Goods Order No. 91 - Standard for labels of prescription
and related medicines in that the product packaging (ampoule label) do not
include the active ingredient in a text height of at least 2.0 millimetres; and
the approved route of administration for the medicine is not captured on the
ampoules.
Import, Supply, &/or Export
Supply
Therapeutic product type
Prescription medicines